EphB4 / HTK Antibody (Antigen Affinity Purified)

Ephrin Type-B Receptor 4 ( EphB4 / HTK ) Antibody ( Antigen Affinity Purified )

EphB4 / HTK Antibody Product Information

• Immunogen: Recombinant human EphB4 protein ( Catalog#10235-H08H )
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: Produced in rabbits immunized with purified, human cell-derived, recombinant human EphB4 extracellular domain ( rhEphB4; Catalog#10235-H08H; NP_004435.3; Met 1-Ala 539 ). EphB4 specific IgG was purified by human EphB4 affinity chromatography.

EphB4 / HTK Antibody Usage Guide

• Specificity: Human EphB4 / HTK
• Western blot: This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human EphB4 in WB. Using a DAB detection system, the detection limit for Human EphB4 is approximately 1 ng/lane under non-reducing conditions and 2 ng/lane under reducing conditions.
• Direct ELISA: This antibody can be used at 0.5 -1.0 μg/mL with the appropriate secondary reagents to detect EphB4. The detection limit for human EphB4 is 0.0049 ng/well.
• Storage: This antibody can be stored at 2℃-8℃ for 1 month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

EphB4 / HTK Antibody Background

EphB4, also known as Htk, Myk-1, is a member of the Eph family of receptor tyrosine kinases (RTK). The Ephs are divided into two classes based on their extracellular structure and ligand specificity, and the transmembrane receptor binding preferentially to ephrin-B ligands is referred to as EphB. Sharing common structure organization, all Eph receptors contain an N-terminal Ig-like domain, a cysteine-rich region and two fibronectin type I II domains within the ECD, as well as the typical cytoplasmic tyrosine kinase domain. EphB4 and its ligand ephrin-B2 are specifically expressed on venous and arterial endothelial cells, respectively, and play an essential role in vascular development via bidirectional signals. The forward EphB4 signaling inhibits cell adhesion, chemotaxis, angiogenesis, and tumor growth. In contrast, the reverse Ephrin-B2 signaling exerts the opposite effect. It has been reported that aberrant expression of EphB4 is associated with prostate cancer and highly malignant breast cancers, and accordingly, EphB4 has potential applications as a therapeutic candidate.

References

1. Bennett, BD. et al., 1994, J. Biol. Chem. 269: 14211-8.
2. Noren, NK. et al., 2004, Proc. Natl. Acad. Sci. 101: 5583-8.
3. Murai, KK. et al., 2003, J. Cell. Sci. 116: 2823-32.
4. Noren, NK. et al., 2006, Nat. Cell. Biol. 8: 815-25.
5. Xia, G. et al., 2005, Cancer Res. 65: 4623-32.
6. Kertesz, N. et al., 2006, Blood. 107: 2330-38.